FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281296119> ?p ?o ?g. }

• W4281296119 endingPage "233" @default.
• W4281296119 startingPage "227" @default.
• W4281296119 abstract "Content available: Audio Recording Metabolic associated fatty liver disease (MAFLD) encompasses a broad disease spectrum that impacts an estimated one billion people worldwide.1 Initially described as non-alcoholic fatty liver disease (NAFLD) in 1980, there is now increasing recognition that the absence of excess alcohol use may be insufficient to characterize this disease process, and interaction between several metabolic risk factors leads to an array of dynamic phenotypes. Although this paradigm change could ultimately help guide new therapeutic strategies, multiple barriers continue to pose clinical care and discovery challenges, including disease heterogeneity, natural history variability, imperfect nomenclature, and suboptimal diagnostic and surveillance tools (Table 1). The application of precision medicine may hold promise for meaningful progress in the future. Phenotypes for MAFLD occur in the context of multiple metabolic risk factors that affect hepatic lipid accumulation, inflammation, and fibrosis. They include demographic traits (age, sex, and ethnicity), lifestyle characteristics (diet, tobacco and alcohol use, and weight), medical comorbidities (glucose intolerance, diabetes mellitus, and other endocrinopathies), surgical interventions (cholecystectomy), intestinal microbiomic composition, genetics, epigenetics, and metabolomics.1, 2 These elements contribute to both established and evolving phenotypes. Among the established MAFLD phenotypes, the traditional phenotype includes individuals with excess weight, a history of minimal-to-moderate alcohol use and, and comorbidities such as diabetes mellitus, hypertension, dyslipidemia, and vascular disease. It is particularly common among Caucasians and captures approximately 80% of patients with MAFLD.3 Disease progression among patients with this phenotype is typically limited. Only a small fraction develops cirrhosis, and the average rate of progression is several years to decades between fibrosis stages.2, 4 Alternatively, lean MAFLD is observed more frequently in the East Asian population, occurring in non-obese individuals with possible genetic predisposition, intestinal dysbiosis, and endocrinopathies; it portends an increased risk for advanced liver disease.5 Finally, Hispanic patients suffer excess burden from MAFLD, with higher disease prevalence and relatively faster progression; although this phenotype is likely multifactorial in etiology, common genetic variants have been identified.6, 7 Overall, among patients with MAFLD, the risks of hepatic decompensation, cardiovascular events, and malignancy are well-described (Fig. 1).8-12 Although these phenotypes have become increasingly recognized in the medical community, they lack the necessary granularity for clinical practice and research. Through the use of precision medicine tools, diverse genetic, epigenetic, and metabolomic signatures can ultimately be used to identify specific and targetable phenotypes. The building blocks for this approach currently exist, but future studies are necessary to determine how different types of molecular data can be synthesized in ways that are applicable for clinicians and researchers. Before this can be accomplished, barriers in diagnosis and staging will likely need to be overcome. The diagnosis of MAFLD currently depends on a combination of clinical, laboratory, and radiographic assessments that include individuals’ risk factor profiles, basic labs and liver chemistries, serological testing to exclude alternative forms of liver disease, and relevant imaging findings, including features of hepatic steatosis and/or fibrosis. In conjunction with the diagnostic evaluation, an early determination of the presence and severity of fibrosis is critical given its association with all-cause and cardiovascular mortality.13 Non-invasive tools, including clinical scoring systems, plasma biomarkers, and elastography, are currently used to identify those with MAFLD, MAFLD with steatohepatitis, and MAFLD with advanced fibrosis. In particular, transient elastography (FibroScan), shear wave elastography, and MR elastography are well-established tools that allow for non-invasive assessment of hepatic fibrosis.14 Unfortunately, a number of these modalities lack the diagnostic discrimination for intermediate fibrosis stages, as well as identification of those with high steatohepatitis inflammatory activity. Thus, these diagnostic tests are likely not adequately sensitive to identify high-risk patients, particularly those seeking enrollment in clinical trials. However, recent multi-national validation of the FibroScan-AST is one example of a risk score developed to identify those individuals with MAFLD, high inflammatory activity, and moderate-to-advanced fibrosis for clinical trial enrollment.15 Finally, a lack of consistent nomenclature also continues to pose challenges, limiting the transition of phenotypic concepts to the clinical medicine. The term “MAFLD” is potentially more representative and inclusive than “NAFLD,” highlighting the premise that metabolic stress dictates phenotypes (and not alcohol use) and emphasizes that MAFLD is not a diagnosis of exclusion. However, it remains imperfect largely due to lack of specificity. Replacing the phrase “non-alcoholic” with a general term such as “metabolic associated” can create ambiguity among providers and researchers since metabolic dysregulation plays a role in a multitude of disease processes that impact the liver. Frequent changes in nomenclature may also lead to confusion among non-hepatologists and lead to barriers in interdisciplinary practices. Future clinical care and research in MAFLD, therefore, is heavily contingent on appropriate host identification, specific and consistent nomenclature, and the application of non-invasive, widely available, effective, and dynamic diagnostic and staging tools that incorporate precision medicine techniques. Genome- and phenome-wide association studies in obese and non-obese patients of different ethnic backgrounds have identified single nucleotide polymorphisms in candidate genes that impact processes such as lipid remodeling, lipid metabolism, glycogen storage, and/or lipophagy (Table 2).16-18 The effects of PNPLA3 polymorphisms have been evaluated in multiple epidemiologic studies, and findings suggest that specific variants can impact disease severity, progression, and responses to intervention. In particular, the PNPLA3 G risk allele is associated with an earlier age of diagnosis, especially among Hispanic patients, and M-variants have been associated with an increased risk for adverse outcomes, including hepatic decompensation, hepatocellular carcinoma, and death.6, 7 Patients with the I148M polymorphism have been shown to have limited responses to statin use and may derive significant benefits from dietary modification.19 Factors that impact gene regulation such as differential DNA methylation and miRNA expression have also been implicated in the pathogenesis and progression of MAFLD. Epigenome-wide association studies and microarrays have identified a subset of genes and miRNA sequences that impact lipid metabolism and inflammation in MAFLD (Table 2).20, 21 The addition of metabolomics to genetic and epigenetic data, microbiomics, and additional surrogate markers may enable targeted clinical research in MAFLD. Studies have already highlighted its potential impact by demonstrating that metabolic profiles incorporating lipid, carbohydrate, amino acid, bacterial, and/or bile acid markers from plasma, urine, or stool samples can be used to identify disease subtypes, monitor for disease progression, assess the risk for outcomes such as cardiovascular disease and cancer, and even discriminate between MAFLD fibrosis stages, in some cases outperforming standard scoring systems for the detection of advanced fibrosis (Table 2).22-30 In particular, changes in the levels of particular amino acids (branched chain and glutathione metabolites) and alterations in fatty acid and bile salt composition have been studied. Increased levels of branched-chain amino acids, increased frequency of fatty acids with low carbon number and double bonds, and a preferential increase in primary bile acids may signify metabolically active MAFLD, whereas with disease progression, one may expect decreased levels of branched-chain amino acids and significant reductions in glutathione precursors.22 Biomarker panels, which can be used to rapidly measure multiple metabolite levels using spectroscopy or chromatography, offer clinicians, patients, and researchers the possibility of trending disease activity and monitoring therapeutic responses in a much more robust manner, overcoming many of the limitations posed by conventional tools. Finally, a number of MR-based biomarkers and methods, including proton density fat fraction (PDFF), spectroscopy, T1 mapping, gadoxetate, and multiparametric imaging, have been studied in the detection of steatosis, steatohepatitis, fibrosis, and hepatocyte function in MAFLD.31 Unfortunately, the application of some of these techniques are limited by technological constraints (availability of specialized scanners). However, PDFF is readily available and has been applied longitudinally to track disease activity. Studies have demonstrated that changes in liver fat content measured via PDFF correlate with changes histologic disease activity, including fibrosis.32, 33 MAFLD is a heterogeneous disease with diverse phenotypes that incorporate a variety of risk factors. The spectrum of disease activity is vast, and outcomes can differ markedly among patients. However, our current diagnostic and therapeutic approaches are homogenous and rely largely on insensitive tools that are insufficient to identify the varied phenotypes in MAFLD. The rise of precision medicine in the form of genetic, epigenetic, metabolomic, and microbiomic techniques will help overcome these challenges as the burden of MAFLD continues to increase globally. In the future, it may become possible to screen high-risk patients with a combination of genetic testing and metabolomic assays that augment conventional modalities, such as elastography and serological studies. The results of these assays can be used to phenotype patients using specific terminology, readily monitor the impact of conventional and experimental treatments, serve as the basis for new highly targeted molecular therapies, and inform prognosis (Fig. 2). The application of machine learning can potentially further improve the efficacy and efficiency of these precision medicine tools. Although additional research will be required to understand how different types of data can be synthesized to develop more holistic diagnostic and treatment models, precision medicine will ultimately change the landscape of MAFLD. Initiatives, such as the Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) project, which aim to accomplish this goal, have been established. Armed with new tools, researchers and clinicians will soon be able to apply molecular techniques to accurately identify and monitor patients and tailor therapies based on personalized molecular signatures." @default.
• W4281296119 created "2022-05-24" @default.
• W4281296119 creator A5001220024 @default.
• W4281296119 creator A5069426951 @default.
• W4281296119 date "2022-05-23" @default.
• W4281296119 modified "2023-09-27" @default.
• W4281296119 title "Clinical Phenotyping and the Application of Precision Medicine in MAFLD" @default.
• W4281296119 cites W1975567145 @default.
• W4281296119 cites W2062618014 @default.
• W4281296119 cites W2063437798 @default.
• W4281296119 cites W2462595066 @default.
• W4281296119 cites W2611418622 @default.
• W4281296119 cites W2622132351 @default.
• W4281296119 cites W2773524446 @default.
• W4281296119 cites W2791490387 @default.
• W4281296119 cites W2797892959 @default.
• W4281296119 cites W2801297606 @default.
• W4281296119 cites W2883511167 @default.
• W4281296119 cites W2894212579 @default.
• W4281296119 cites W2903951040 @default.
• W4281296119 cites W2921476121 @default.
• W4281296119 cites W2946969390 @default.
• W4281296119 cites W2968129333 @default.
• W4281296119 cites W2970223292 @default.
• W4281296119 cites W2971152979 @default.
• W4281296119 cites W2988888263 @default.
• W4281296119 cites W3004644667 @default.
• W4281296119 cites W3004950447 @default.
• W4281296119 cites W3006556627 @default.
• W4281296119 cites W3009821608 @default.
• W4281296119 cites W3015361084 @default.
• W4281296119 cites W3019437271 @default.
• W4281296119 cites W3020200374 @default.
• W4281296119 cites W3023600519 @default.
• W4281296119 cites W3028548828 @default.
• W4281296119 cites W3046839136 @default.
• W4281296119 cites W3092264591 @default.
• W4281296119 cites W3095035989 @default.
• W4281296119 cites W3123804908 @default.
• W4281296119 cites W3169979574 @default.
• W4281296119 cites W3197814387 @default.
• W4281296119 doi "https://doi.org/10.1002/cld.1199" @default.
• W4281296119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35795621" @default.
• W4281296119 hasPublicationYear "2022" @default.
• W4281296119 type Work @default.
• W4281296119 citedByCount "2" @default.
• W4281296119 countsByYear W42812961192023 @default.
• W4281296119 crossrefType "journal-article" @default.
• W4281296119 hasAuthorship W4281296119A5001220024 @default.
• W4281296119 hasAuthorship W4281296119A5069426951 @default.
• W4281296119 hasBestOaLocation W42812961192 @default.
• W4281296119 hasConcept C142724271 @default.
• W4281296119 hasConcept C15744967 @default.
• W4281296119 hasConcept C163763905 @default.
• W4281296119 hasConcept C41008148 @default.
• W4281296119 hasConcept C71924100 @default.
• W4281296119 hasConceptScore W4281296119C142724271 @default.
• W4281296119 hasConceptScore W4281296119C15744967 @default.
• W4281296119 hasConceptScore W4281296119C163763905 @default.
• W4281296119 hasConceptScore W4281296119C41008148 @default.
• W4281296119 hasConceptScore W4281296119C71924100 @default.
• W4281296119 hasIssue "6" @default.
• W4281296119 hasLocation W42812961191 @default.
• W4281296119 hasLocation W42812961192 @default.
• W4281296119 hasLocation W42812961193 @default.
• W4281296119 hasOpenAccess W4281296119 @default.
• W4281296119 hasPrimaryLocation W42812961191 @default.
• W4281296119 hasRelatedWork W1489783725 @default.
• W4281296119 hasRelatedWork W1506200166 @default.
• W4281296119 hasRelatedWork W2039318446 @default.
• W4281296119 hasRelatedWork W2048182022 @default.
• W4281296119 hasRelatedWork W2080531066 @default.
• W4281296119 hasRelatedWork W2604872355 @default.
• W4281296119 hasRelatedWork W2748952813 @default.
• W4281296119 hasRelatedWork W2899084033 @default.
• W4281296119 hasRelatedWork W3032375762 @default.
• W4281296119 hasRelatedWork W3108674512 @default.
• W4281296119 hasVolume "19" @default.
• W4281296119 isParatext "false" @default.
• W4281296119 isRetracted "false" @default.
• W4281296119 workType "article" @default.